Table 1.

Patient’s demographics and lymphedema characteristics

		Group I (night-use) N = 20	Group II (no night-use) N = 20	Total N = 40
Age at inclusion (years)	N	20	20	40
	Mean ± SD	65.11 ± 8.62	68.87 ± 11.79	66.99 ± 10.37
	Median	64.47	72.01	66.31
	Min; max	50.5; 84.5	45.3; 89.9	45.3; 89.9
Body mass index (kg m−2) at day 0[b]	N	20	20	40
	Mean ± SD	27.44 ± 4.54	29.63 ± 6.53	28.53 ± 5.66
	Median	28.09	29.08	28.81
	Min ; Max	20.4; 34.3	19.8; 44.0	19.8; 44.0
Time since diagnosis of breast cancer (years)	N	20	20	40
	Mean ± SD	12.72 ± 9.87	15.40 ± 11.21	14.06 ± 10.51
Prior therapies for breast cancer	N	20	20	40
Surgery		20 (100.0%)	20 (100.0%)	40 (100.0%)
Time since latest surgery (years)	Mean ± SD	10.78 ± 8.80	12.44 ± 9.39	11.61 ± 9.02
Type of surgery
	Tumorectomy	5 (25.0%)	7 (35.0%)	12 (30.0%)
	Tumorectomy + sentinel lymph node removal and/or entire lymph node removal	5 (25.0%)	7 (35.0%)	12 (60%)
	Mastectomy	3 (15.0%)	3 (15.0%)	6 (15.0%)
	Mastectomy + entire lymph node removal or entire lymph node removal	7 (35.0%)	3 (15.0%)	10 (50.0%)
	Sentinel lymph node removal	0 (0.0%)	0 (0.0%)	0 (0.0%)
Radiotherapy		20 (100.0%)	20 (100.0%)	40 (100.0%)
Chemotherapy		12 (60.0%)	12 (60.0%)	24 (60.0%)
Hormone therapy	N	7 (35.0%)	7 (35.0%)	14 (35.0%)
Time since lymphedema diagnosis (years)	N	20	20	40
	Mean ± SD	7.08 ± 5.52	9.62 ± 7.98	8.35 ± 6.90
	Median	7.00	7.13	7.00
	Min; Max	0.5; 20.5	0.5; 28.7	0.5; 28.7
Lymphedema stage	N	20	20	40
	Stage II	20 (100.0%)	17 (85.0%)	37 (92.5%)
	Stage III	0 (0.0%)	3 (15.0%)	3 (7.5%)
Pitting signs	N	20	20	40
	Absent	0 (0.0%)	0 (0.0%)	0 (0.0%)
	+	0 (0.0%)	0 (0.0%)	0 (0.0%)
	++	18 (90.0%)	17 (85.0%)	35 (87.5%)
	+++	2 (10.0%)	3 (15.0%)	5 (12.5%)
	++++	0 (0.0%)	0 (0.0%)	0 (0.0%)